Compare GSK plc (GSK) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Ryanair Holdings plc — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while Ryanair Holdings plc trades at $66.44 (market cap $31.83B). The key difference: GSK plc is far larger — about 3.2× Ryanair Holdings plc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | RYAAY | |
|---|---|---|
Market Cap | $101.34B | $31.83B |
Sector | Health | Industrials |
52-Week High | $61.18 | $73.82 |
52-Week Low | $36.20 | $53.24 |
Enterprise Value | $121.95B | $29.49B |
Dividend Yield | 3.49% | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
RYAAY trades at $66.29, up 3.11% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 14.32, net income margin of 13.98%, and consistent earnings beats. Recent news highlights passenger growth and operational updates, though a window incident adds scrutiny. Cash flow remains positive from operations at $3.42B despite negative net cash flow.
Outlook is positive with analyst consensus at 62.5% buy ratings. Revenue growth to $15.5B projected for 2026 supports upside, but risks include fuel cost volatility and regulatory pressures. The stock's valuation and profitability metrics present an attractive entry for long-term investors amid sector recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
